RecruitingPhase 2NCT06736613

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Cerebral Spinal Fluid Circulating Tumor DNA (ctDNA) Analysis in Patients With Aggressive B-cell Lymphoma Receiving Front Line Therapy and at High Risk for Central Nervous System Relapse

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

50 participants

Start Date

Dec 11, 2024

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Stage III High Grade B-Cell Lymphoma Stage IV High Grade B-Cell Lymphoma DLBCL - Diffuse Large B Cell Lymphoma Intravascular Large B-Cell Lymphoma Diffuse Large B Cell Lymphoma of Breast Diffuse Large B Cell Lymphoma of Testis HIV-associated Diffuse Large B Cell Lymphoma Double Expressor DLBCL

Summary

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse happens in people with and without detected CSF ctDNA.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a liquid biopsy blood test — which detects fragments of cancer DNA floating in the blood (called circulating tumor DNA or ctDNA) — can help predict which patients with aggressive B-cell lymphoma are at risk of cancer spreading to the brain. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with one of several high-risk B-cell lymphoma subtypes, such as diffuse large B-cell lymphoma (DLBCL) with a high CNS IPI score, high-grade B-cell lymphoma with specific gene changes (MYC, BCL2, BCL6), or primary DLBCL of the breast or certain other sites - You are willing and able to provide blood samples **You may NOT be eligible if...** - You do not have a qualifying lymphoma diagnosis or high-risk criteria - You are unable or unwilling to comply with study requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTCerebral Spinal Fluid ctDNA

MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019